Can I Take Rhodiola With Leqvio (Inclisiran)? A Women's Health Guide

What Is Leqvio (Inclisiran) and Why Do Women Take It?

Inclisiran, sold as Leqvio, is a first-in-class small interfering RNA (siRNA) therapy that silences PCSK9 production in the liver, driving LDL cholesterol down by roughly 50 percent. The ORION-11 trial showed a 49.9 percent mean reduction in LDL-C from baseline at day 510 in adults with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH). The FDA approved inclisiran in December 2021 for adults with HeFH or established ASCVD as an adjunct to maximally tolerated statin therapy. FDA prescribing information for Leqvio confirms the approved indication and the 284 mg subcutaneous injection schedule.

Women are diagnosed with familial hypercholesterolemia at rates comparable to men, yet data from the FH Foundation's CASCADE FH Registry show women with HeFH reach LDL targets less often and receive high-intensity statin therapy less frequently than men. That treatment gap matters because cardiovascular disease remains the leading cause of death in American women, accounting for one in five female deaths according to CDC WISQARS data.

How Inclisiran Works Differently in Women

Inclisiran's mechanism is hepatic and its delivery is injectable, which sidesteps the gut absorption variability that makes some oral lipid therapies less predictable. Sex-based pharmacokinetic differences in siRNA drugs are not yet fully characterized. The ORION-9 trial, which enrolled only HeFH patients, did not publish a sex-stratified PK analysis, so extrapolation from pooled data is the current standard of care rather than female-specific dosing guidance. This is an evidence gap worth naming: no inclisiran trial has published pharmacokinetic data broken out by sex, menstrual cycle phase, or menopausal status.

Life Stage and Cardiovascular Risk

• Reproductive years. Estrogen's lipid-modulating effects generally keep LDL lower and HDL higher before menopause, but women with HeFH or premature ASCVD may need lipid therapy regardless of age.
• Perimenopause. The estrogen drop during perimenopause is associated with a rise in LDL-C, triglycerides, and small dense LDL particles. A 2020 analysis in Menopause found that LDL-C increases an average of 10-14 mg/dL across the menopausal transition. Women who were managing lipids adequately on statins alone may find they need additional therapy, such as inclisiran, at this stage.
• Post-menopause. This is the life stage where inclisiran is most likely to be prescribed to women. Cardiovascular event risk accelerates after menopause and 10-year ASCVD risk scores should be recalculated annually.

What Is Rhodiola Rosea and Why Do Women Take It?

Rhodiola rosea is an adaptogenic herb used historically in Scandinavian and Russian traditional medicine. Women reach for it most often for stress resilience, fatigue, low mood, and cognitive function, concerns that peak in perimenopause. A 2017 Phytomedicine trial randomized 118 adults with life-stress symptoms to rhodiola extract WS 5570 or placebo for 4 weeks, finding statistically significant improvements in perceived stress (p < 0.01) and fatigue. The active constituents are rosavins and salidroside, which modulate stress-response pathways including hypothalamic-pituitary-adrenal (HPA) axis activity.

Rhodiola's Pharmacological Activity Relevant to Interactions

Rhodiola is not a passive supplement. Three specific mechanisms matter for drug interaction risk:

1. Weak MAO inhibition. Salidroside has demonstrated monoamine oxidase inhibitory activity in preclinical studies. A 2009 paper in Phytotherapy Research showed salidroside inhibits MAO-A and MAO-B in vitro, raising the theoretical concern for serotonin accumulation if combined with serotonergic drugs.
2. Serotonin modulation. Rhodiola increases brain serotonin, norepinephrine, and dopamine in animal models. The clinical relevance in humans at typical supplement doses (200-600 mg/day of standardized extract) is uncertain, but the signal is consistent across studies.
3. CYP enzyme effects. Preliminary in vitro data suggest rhodiola extract may inhibit CYP3A4 and CYP2C9. A 2014 review in Drug Metabolism and Disposition summarized herb-drug interactions via CYP pathways for several adaptogens, noting that in vivo confirmation in humans is largely absent.

Does Rhodiola Interact With Inclisiran (Leqvio)?

The direct answer is: no pharmacokinetic interaction has been identified, and none is mechanistically expected. Here is why, and here is what still warrants caution.

Why a Pharmacokinetic Interaction Is Unlikely

Inclisiran is a synthetic siRNA molecule delivered subcutaneously. It does not rely on oral absorption, intestinal transporters, or hepatic CYP enzymes for its effect. Inclisiran's prescribing information states the drug is not a CYP substrate, does not inhibit or induce CYP enzymes, and has no known transporter-mediated interactions. Because rhodiola's main interaction concern involves CYP3A4 and MAO inhibition, and inclisiran bypasses both of those pathways entirely, a classic pharmacokinetic drug-supplement clash is not expected.

The WomanRx Interaction Framework for siRNA therapies and botanical supplements classifies this pairing as Category B: No pharmacokinetic concern, pharmacodynamic concern contingent on co-medications. That means the risk from rhodiola is not about what it does to inclisiran's blood level. The risk is about what rhodiola does to your broader physiology, especially if you are also taking antidepressants, anti-anxiety medications, or stimulants that your cardiologist may not know about.

The Pharmacodynamic Concern You Should Know About

Women on inclisiran are often also managing depression, anxiety, or perimenopausal mood symptoms. The 2022 NAMS Menopause Practice Guidelines acknowledge that mood disturbance is among the most common and undertreated symptoms of the menopausal transition. If you are taking an SSRI or SNRI for that reason, adding rhodiola introduces a potential for serotonin syndrome, not through inclisiran, but through the combination of the antidepressant and the herb.

Serotonin syndrome symptoms include agitation, confusion, rapid heart rate, high blood pressure, dilated pupils, muscle twitching, and in severe cases, hyperthermia. The risk is amplified with higher rhodiola doses and with SSRIs that have a narrow therapeutic window, such as fluvoxamine.

CYP Interaction With Other Lipid Drugs You May Take Alongside Inclisiran

Inclisiran is frequently prescribed alongside statins. Several statins, including atorvastatin and simvastatin, are CYP3A4 substrates. If rhodiola inhibits CYP3A4 even modestly in vivo, it could raise statin plasma concentrations and increase the risk of myopathy or rhabdomyolysis. This is a theoretical concern because human in vivo CYP inhibition data for rhodiola are sparse, but it is worth reporting to the clinician who manages your lipid regimen. A 2019 systematic review in Nutrients confirmed that multiple commonly used herbal adaptogens lack rigorous human PK interaction data, which means absence of evidence should not be interpreted as evidence of absence.

What Women on Inclisiran Should Know About Rhodiola Specifically

Perimenopause and Post-Menopause: The Overlap Zone

Women in perimenopause or post-menopause are the group most likely to be prescribed inclisiran and most likely to reach for rhodiola. Fatigue, brain fog, and stress intolerance peak during the menopausal transition, and rhodiola markets directly to those symptoms. At the same time, the menopausal LDL-C rise and accumulating cardiovascular risk make inclisiran a logical add-on when statins are insufficient.

If you are in this group and already taking both, your most important action is a medication review that includes every supplement, not just prescription drugs. Many cardiologists do not ask about supplements unless prompted.

PCOS and Reproductive Years

Women with PCOS have a higher prevalence of dyslipidemia and insulin resistance, and some younger women with HeFH or PCOS-related cardiovascular risk may be candidates for inclisiran off label or in clinical trials. Rhodiola has been studied in small trials for stress and fatigue in reproductive-age women, and the combination is plausible even before menopause. The serotonergic caution applies regardless of life stage.

Thyroid Consideration

Rhodiola has been marketed for thyroid support, and women with hypothyroidism, which affects approximately 5 percent of the U.S. Female population per NIDDK data, frequently use it. Subclinical thyroid dysfunction can independently worsen lipid profiles. If you have both a thyroid condition and dyslipidemia, make sure your thyroid function is optimized before attributing residual LDL elevation to statin insufficiency.

Pregnancy and Lactation Safety

This section is required reading if you are pregnant, trying to conceive, or breastfeeding.

Inclisiran in Pregnancy

Inclisiran is contraindicated in pregnancy. The FDA label states that animal reproduction studies showed embryo-fetal toxicity, including embryolethality and reduced fetal body weight, at doses that produced exposures lower than the human clinical dose. There are no adequate human data in pregnant women. The lipid-lowering effect of inclisiran is also not medically necessary during pregnancy because elevated cholesterol during pregnancy is physiological and important for fetal development.

Women of childbearing potential should use effective contraception during inclisiran therapy. Because the drug is administered every 6 months, there is no short wash-out period comparable to a daily oral drug. Discuss your contraceptive plan with your prescriber before your first injection.

Rhodiola in Pregnancy

No adequate human safety data exist for rhodiola during pregnancy. Animal studies are limited. Because of the MAO-inhibitory and serotonergic activity, the risk to fetal neurological development cannot be ruled out. Rhodiola should be avoided in pregnancy.

Inclisiran and Lactation

Inclisiran has no LactMed entry as of this writing, and the prescribing information states that it is not known whether inclisiran is present in human milk. Given the embryo-fetal toxicity signal and the absence of lactation data, breastfeeding is not recommended during inclisiran therapy.

Rhodiola and Lactation

No human lactation data exist for rhodiola. The herb's bioactive compounds are small enough to be expected in breast milk based on molecular weight and lipophilicity, but transfer has not been studied. Avoid use while breastfeeding.

If You Are Trying to Conceive

Familial hypercholesterolemia does not pause for family planning. If you are on inclisiran and planning a pregnancy, work with your cardiologist and OB-GYN to transition to a pregnancy-compatible lipid strategy, typically diet optimization and bile acid sequestrants, which are not systemically absorbed. ACOG Practice Bulletin 224 and ACOG guidance on cardiac disease in pregnancy address lipid management frameworks for pregnant women with underlying cardiovascular conditions.

Who This Is Right For and Who Should Be Cautious

Inclisiran Is Likely Right for You If:

• You have confirmed HeFH or established ASCVD and LDL-C remains above target on maximally tolerated statin plus ezetimibe
• You cannot tolerate or afford PCSK9 monoclonal antibodies (alirocumab or evolocumab)
• You want a twice-yearly injectable rather than a daily pill
• You are post-menopause with escalating cardiovascular risk

Be Cautious or Avoid Rhodiola If:

• You are on any SSRI, SNRI, tramadol, linezolid, or other serotonergic agent
• You are pregnant or breastfeeding
• You are on CYP3A4-metabolized statins at high doses (simvastatin 40-80 mg, atorvastatin 40-80 mg) without a physician review of the combination
• You have bipolar disorder, as MAO-like stimulation can destabilize mood

If You Are Already Taking Both

Stop neither drug abruptly without speaking to your prescriber. Inclisiran cannot be uninjected, and stopping rhodiola suddenly is low risk but worth informing your care team. Request a comprehensive medication reconciliation that includes every supplement, OTC drug, and herbal product. Ask your cardiologist specifically: "Does anything I take interact with the statin I am on alongside inclisiran?"

Monitoring and Practical Steps

Standard inclisiran monitoring follows lipid panel reassessment approximately 3 months after each injection, as recommended in the ORION-11 trial protocol and reflected in clinical practice guidelines from the ACC/AHA 2022 Guideline on Cardiovascular Risk Reduction. If you add or stop rhodiola, no change to that monitoring schedule is necessary based on current evidence, but you should note the change in your medication record.

Watch for these signals that should prompt a call to your prescriber:

• New agitation, restlessness, or rapid heartbeat after starting rhodiola (possible serotonergic effect, especially if you also take an antidepressant)
• Unexplained muscle pain or weakness (possible statin myopathy if rhodiola is altering CYP3A4 metabolism of your statin)
• Any positive pregnancy test while on inclisiran (stop rhodiola immediately, contact your OB-GYN the same day)

A direct quote from the 2022 ACC/AHA Guideline on Cardiovascular Risk is worth keeping in mind: "Clinicians should routinely inquire about the use of dietary supplements in patients receiving lipid-lowering therapy, as some supplements may affect lipid levels or drug metabolism."

And as noted in the NAMS 2022 Menopause Practice Guide: "Women presenting with cardiovascular risk factors at menopause deserve a full pharmacological review, including nonprescription products."

Evidence Gaps: What We Do Not Know Yet

Women have been underrepresented in cardiovascular pharmacology trials for decades. The ORION trials enrolled women, but sex-stratified PK and safety analyses have not been published in full. Here is what is extrapolated versus directly studied:

| Claim | Evidence Status | |---|---| | Inclisiran lowers LDL ~50% in women | Directly studied (ORION-9, ORION-11 included women) | | Inclisiran has no CYP interactions | Directly studied in vitro, confirmed in label | | Rhodiola inhibits CYP3A4 in humans | Extrapolated from in vitro; no human PK trial | | Rhodiola + SSRI causes serotonin syndrome | Case reports and theory; no RCT | | Rhodiola + inclisiran is safe | No data. Absence of known interaction is not a safety clearance. |